An 18-month-old, previously well boy presents to his primary care pediatrician with a 2-day history of fever, fussiness, and what his mother interprets as a sore throat because he is crying, eating ...

A Prescription Drug User Fee Act target date of June 20, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...

For centuries, bullous pemphigoid (BP) was grouped with and considered a condition similar to pemphigus vulgaris (PV). In 1953, however, Lever recognized BP as a disorder distinct from PV. 9 BP, the ...

Findings showed 20% of patients treated with dupilumab experienced sustained disease remission at week 36 compared with 4% of those who received placebo. Treatment with dupilumab led to significant ...

DEAR DR. ROACH: I am a 73-year-old woman who is in otherwise good health, but I was diagnosed with bullous pemphigoid, a rare autoimmune disease, in January 2022. I have been treated by three ...

Please provide your email address to receive an email when new articles are posted on . If approved, Dupixent would be the first and only targeted medicine to treat bullous pemphigoid in the U.S. The ...

Autoimmune bullous diseases comprise a group of conditions characterised by the formation of blisters on the skin and mucous membranes due to aberrant immune responses. Central to many of these ...

(RTTNews) - Drug makers Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Wednesday that ADEPT study of Dupixent (dupilumab) in bullous pemphigoid or BP met the primary and all key ...

An autoimmune blistering disease of the mucous membranes and skin, pemphigus vulgaris (PV) derives its name from the Greek word, pemphix, for blister. 1 PV is characteristically seen in older patients ...